Working… Menu

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02135536
Recruitment Status : Completed
First Posted : May 12, 2014
Last Update Posted : March 28, 2017
NGM Biopharmaceuticals Australia Pty Ltd
Information provided by (Responsible Party):
NGM Biopharmaceuticals, Inc

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : February 2016
Actual Study Completion Date : February 2016
Certification/Extension First Submitted : March 27, 2017